Literature DB >> 27387641

Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives.

Emma Scott1, Diana Learoyd1,2, Roderick J Clifton-Bligh1,2,3.   

Abstract

The treatment of papillary thyroid cancer is now based on individual patient risk and response to therapies. Molecular techniques are increasingly being used to risk stratify and to guide therapeutic decisions. There have been advances in the treatment of local disease through surgery or radioiodine. Directed techniques can target metastatic disease including bisphosphonates, radiofrequency ablation or radiotherapy. Systemic therapies such as tyrosine kinase inhibitors show great promise although such treatment must be individualized. Future therapies will target treating radioiodine refractory disease.

Entities:  

Keywords:  BRAF; TERT; papillary thyroid cancer; radioactive iodine; tyrosine kinase inhibitors

Mesh:

Substances:

Year:  2016        PMID: 27387641     DOI: 10.2217/fon-2016-0171

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  8 in total

Review 1.  BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence.

Authors:  Agnieszka Czarniecka; Małgorzata Oczko-Wojciechowska; Marcin Barczyński
Journal:  Gland Surg       Date:  2016-10

2.  Pyruvate carboxylase promotes malignant transformation of papillary thyroid carcinoma and reduces iodine uptake.

Authors:  Yang Liu; Chang Liu; Yu Pan; Jinxin Zhou; Huijun Ju; Yifan Zhang
Journal:  Cell Death Discov       Date:  2022-10-20

3.  Retracted Article: Overexpression of PCDH8 inhibits proliferation and invasion, and induces apoptosis in papillary thyroid cancer cells.

Authors:  Liang Chang; Zhuang Hu; Zhenyu Zhou; Hui Zhang
Journal:  RSC Adv       Date:  2018-05-16       Impact factor: 4.036

4.  RE: Papillary Thyroid Carcinoma Treated with Radiofrequency Ablation in a Patient with Hypertrophic Cardiomyopathy: A Case Report.

Authors:  Eun-Kyung Kim
Journal:  Korean J Radiol       Date:  2016-10-31       Impact factor: 3.500

5.  HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.

Authors:  Lingxiao Cheng; Yuchen Jin; Min Liu; Maomei Ruan; Libo Chen
Journal:  Oncotarget       Date:  2017-03-21

6.  IL-34 is a potential biomarker for the treatment of papillary thyroid cancer.

Authors:  Ping Zhang; Hao Zhang; Wenwu Dong; Zhihong Wang; Yuan Qin; Changhao Wu; Qi Dong
Journal:  J Clin Lab Anal       Date:  2020-06-23       Impact factor: 2.352

7.  MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF V600E: An In Vitro Study.

Authors:  Hao Fu; Lingxiao Cheng; Yuchen Jin; Lin Cheng; Min Liu; Libo Chen
Journal:  Mol Ther Oncolytics       Date:  2019-02-05       Impact factor: 7.200

8.  S100A12 is a promising biomarker in papillary thyroid cancer.

Authors:  Xiaojie Wang; Zhenxiang Sun; Wei Tian; Chenghao Piao; Xiaochen Xie; Jin Zang; Shiqiao Peng; Xiaohui Yu; Yiwei Wang
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.